{
  "docId": "019de073-187a-71e9-a3c0-2f4159454068",
  "docSlug": "48ce63a07f3c546c39a71c96ea43409e",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 40 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 40,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "The slide uses a 3-column layout for the top section and a full-width block for the bottom section to categorize strategic initiatives.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-187a-71e9-a3c0-2f4159454068/6",
  "deckHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068",
  "deckJsonHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068.json",
  "deckAnchorHref": "/decks/019de073-187a-71e9-a3c0-2f4159454068#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.13,
        "y": 0.245
      },
      "kind": "list",
      "text": "Unprecedented pipeline delivery: 13 Phase III starts, 5 positive pivotal trial read outs, 20 submission acceptances, >120 projects in Phase II/III",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f7f3cf9-ced2-4d63-89fe-92b40735ed2f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.65,
        "y": 0.245
      },
      "kind": "list",
      "text": "Investment in discovery and new technology: ADCs, Cell therapy, PROTACs, T-Cell engagers, Oligo/mRNA-based therapies, Computational pathology, AI & machine learning",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "af3a4360-423e-4091-ba81-bf193fd88f63",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.77,
        "x": 0.13,
        "y": 0.67
      },
      "kind": "list",
      "text": "Driving continuous productivity improvements: Remote clinical trial capabilities, Process improvements, Internalisation of clinical operations, Rigorous portfolio prioritisation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e22617ae-f93a-4f28-b3c4-7d99d4b6b1f5",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.39,
        "y": 0.245
      },
      "kind": "list",
      "text": "Data-driven expansion for high value opportunities: Dato-DXd, Enhertu, AZD5305, IO bispecifics, tozorakimab, eplontersen",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f3785195-bdf8-46a5-b0fe-a85212c390e6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.55,
        "x": 0.4,
        "y": 0.96
      },
      "kind": "source-note",
      "text": "Dato-DXd = datopotamab deruxtecan; PARP-1 sel = Poly [ADP-ribose] polymerase 1 selective; ADC = antibody drug conjugates; IO = immuno-oncology; PROTACs = PROteolysis TArgeting Chimeras; Oligo = oligonucleotides; AI = artificial intelligence; VEGF = vascular endothelial growth factor; DNAPK = DNA-dependent protein kinase.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2c16843c-4d5e-45fa-a703-9d7d25217bd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.03,
        "y": 0.14
      },
      "kind": "title",
      "text": "Investing efficiently to deliver long-term sustainable growth",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0d101bab-f6fc-40d6-8af6-e18fbcbb596a",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.21,
        "x": 0.03,
        "y": 0.06
      },
      "kind": "title",
      "text": "AstraZeneca",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "70c777c0-9e13-47cf-9700-bebc9da23459",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "e0c73493-0c69-4685-9fb4-f7afad3f6bd7",
      "evidence": "list/bullet: Driving continuous productivity improvements: Remote clinical trial capabilities, Process improvements, Internalisation of clinical operations, Rigorous portfolio prioritisation",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}